4th Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals; S. 1357, Affordable Medicines Utilization Act of 2011.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: Patent & Trademark Office (PTO); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S. 296 (112th), S. 1357 (112th), H.R. 5 (112th)

Copyright/Patent/Trademark CPT

S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Bills named: S. 23 (112th), S. 27 (112th), H.R. 1249 (112th)

Trade (domestic/foreign) TRD

U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Patent & Trademark Office (PTO)

Bills named: S. 330 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.